Soma Tablet Particles Show No Adverse Health Effects, MedPointe Tells FDA
Executive Summary
MedPointe expects to address FDA's Soma manufacturing concerns with a final report showing no adverse health effects from black specks found on carisoprodol tablets
You may also be interested in...
MedPointe To Seek Fluorofelbamate Partner After Carter-Wallace Acquisition
MedPointe will likely seek a development partner for the anti-epileptic fluorofelbamate after the company acquires Carter-Wallace's healthcare business.
Transition complete
Former Warner-Lambert Global Pharmaceutical President Anthony Wild, PhD, has formed a specialty pharmaceutical investment fund, MedPointe Capital Partners. Wild was one of the top-ranking Warner-Lambert executives on the transition team following the Pfizer merger. Wild has also joined the Allergan board of directors, replacing former SmithKline Beecham Chairman Henry Wendt
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011